{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:47:42Z","timestamp":1790948862056,"version":"4.1.0"},"reference-count":62,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.18939","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T18:58:43Z","timestamp":1578682723000},"page":"e1918939","source":"Crossref","is-referenced-by-count":63,"title":["Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer"],"prefix":"10.1001","volume":"3","author":[{"given":"Xavier","family":"Paoletti","sequence":"first","affiliation":[{"name":"Groupe d\u2019investigateurs national des Etudes des Cancers Ovariens (GINECO), Paris, France"},{"name":"Gustave Roussy Cancer Center and Institut National de la Sant\u00e9 et de la Recherche Medicale Oncostat, Villejuif, France"},{"name":"Department of Biostatistics, University of Versailles St Quentin, Institut Curie, Saint-Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz-Anne","family":"Lewsley","sequence":"additional","affiliation":[{"name":"Scottish Gynaecological Cancer Trials Group (SGCTG), Cancer Research United Kingdom Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Daniele","sequence":"additional","affiliation":[{"name":"Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Clinical Trials Unit, Istituto Nazionale Tumori\u2013 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Cook","sequence":"additional","affiliation":[{"name":"Medical Research Counsel Clinical Trials Unit, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Yanaihara","sequence":"additional","affiliation":[{"name":"Japanese Gynecologic Oncology Group (JGOG), Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tinker","sequence":"additional","affiliation":[{"name":"Canadian Cancer Trials Group (CCTG), University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Nordic Society of Gynaecological Oncology, Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella B.","family":"Ottevanger","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Aravantinos","sequence":"additional","affiliation":[{"name":"Hellenic Cooperative Oncology Group, General Oncology Hospital of Kifissia, Nea Kifissia, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Miller","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Group (GOG), Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.","family":"Boere","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fruscio","sequence":"additional","affiliation":[{"name":"University of Milan Bicocca, San Gerardo Hospital, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K. L.","family":"Reyners","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[{"name":"Association de Recherche sur les Cancers dont Gyn\u00e9cologiques\u2013GINECO, Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Harkin","sequence":"additional","affiliation":[{"name":"Scottish Gynaecological Cancer Trials Group (SGCTG), Cancer Research United Kingdom Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[{"name":"MITO, Istituto Nazionale Tumori di Napoli IRCCS Fondazione G Pascale, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kagimura","sequence":"additional","affiliation":[{"name":"JGOG, Foundation for Biomedical Research and Innovation at Kobe, Translational Research Center for Medical Innovation, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Welch","sequence":"additional","affiliation":[{"name":"CCTG, London Health Sciences Centre, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Paul","sequence":"additional","affiliation":[{"name":"Scottish Gynaecological Cancer Trials Group (SGCTG), Cancer Research United Kingdom Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Karamouza","sequence":"additional","affiliation":[{"name":"Gustave Roussy Cancer Center, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind M.","family":"Glasspool","sequence":"additional","affiliation":[{"name":"SGCTG, Beatson West of Scotland Cancer Centre, NHS (National Health Service) Greater Glasgow and Clyde, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Gynecologic Cancer InterGroup (GCIG) Meta-analysis Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"issue":"5","key":"zoi190711r1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"17","key":"zoi190711r2","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 8","key":"zoi190711r3","doi-asserted-by":"publisher","first-page":"i30","DOI":"10.1093\/annonc\/mdx449","article-title":"Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.","volume":"28","author":"Bookman","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi190711r4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/PPO.0b013e3181b9c602","article-title":"Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.","volume":"15","author":"Buyse","year":"2009","journal-title":"Cancer J"},{"issue":"1","key":"zoi190711r5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","article-title":"Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers.","volume":"26","author":"S\u00f6l\u00e9tormos","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"zoi190711r6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"16","key":"zoi190711r7","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement.","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"issue":"24","key":"zoi190711r8","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1002\/(ISSN)1097-0258","article-title":"The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials.","volume":"18","author":"Buyse","year":"1999","journal-title":"Stat Med"},{"issue":"19","key":"zoi190711r9","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Practical methodology of meta-analyses (overviews) using updated individual patient data.","volume":"14","author":"Stewart","year":"1995","journal-title":"Stat Med"},{"issue":"11","key":"zoi190711r10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"9814","key":"zoi190711r11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"zoi190711r12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments.","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"issue":"5","key":"zoi190711r14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/0962280207081864","article-title":"Individual- and trial-level surrogacy in colorectal cancer.","volume":"17","author":"Buyse","year":"2008","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"zoi190711r15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients\u2019 data.","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi190711r16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials.","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi190711r17","article-title":"Validation of minimal residual disease as surrogate endpoint for event-free survival in childhood acute lymphoblastic leukemia.","volume":"2","author":"Galimberti","year":"2018","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"24","key":"zoi190711r18","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"zoi190711r19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cmpb.2017.12.005","article-title":"surrosurv: an R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials.","volume":"155","author":"Rotolo","year":"2018","journal-title":"Comput Methods Programs Biomed"},{"issue":"15","key":"zoi190711r20","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.ejca.2008.06.035","article-title":"Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.","volume":"44","author":"Aravantinos","year":"2008","journal-title":"Eur J Cancer"},{"issue":"3","key":"zoi190711r21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/annonc\/mds494","article-title":"A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.","volume":"24","author":"Banerjee","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi190711r22","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/sj.bjc.6604231","article-title":"A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.","volume":"98","author":"Fruscio","year":"2008","journal-title":"Br J Cancer"},{"issue":"2","key":"zoi190711r23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ygyno.2005.12.020","article-title":"A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel\/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.","volume":"102","author":"Hirte","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"20","key":"zoi190711r24","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/jnci\/djq362","article-title":"Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.","volume":"102","author":"Hoskins","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"zoi190711r25","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi190711r26","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1093\/annonc\/mds060","article-title":"First-line treatment of advanced ovarian cancer with paclitaxel\/carboplatin with or without epirubicin (TEC versus TC): a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.","volume":"23","author":"Lindemann","year":"2012","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi190711r27","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"27","key":"zoi190711r28","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.","volume":"29","author":"Pignata","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi190711r29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi190711r30","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/sj.bjc.6604026","article-title":"Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer: a randomised study from the GINECO group.","volume":"97","author":"Ray-Coquard","year":"2007","journal-title":"Br J Cancer"},{"issue":"11","key":"zoi190711r31","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1093\/annonc\/mds107","article-title":"A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, fallopian tube or primary peritoneal carcinomas: the DoCaCel study.","volume":"23","author":"Reyners","year":"2012","journal-title":"Ann Oncol"},{"issue":"24","key":"zoi190711r32","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.2016.66.9010","article-title":"Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG trial.","volume":"34","author":"Sugiyama","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi190711r33","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1016\/j.ejca.2014.07.015","article-title":"Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel\/platinum induction therapy followed by standard or extended three-weekly paclitaxel\/platinum in European patients with advanced epithelial ovarian cancer.","volume":"50","author":"van der Burg","year":"2014","journal-title":"Eur J Cancer"},{"issue":"4","key":"zoi190711r34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1200\/JCO.2013.50.5669","article-title":"Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.","volume":"32","author":"Vergote","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi190711r35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ygyno.2011.03.013","article-title":"A randomized phase III trial of IV carboplatin and paclitaxel \u00d73 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.","volume":"122","author":"Mannel","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"22","key":"zoi190711r36","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"26","key":"zoi190711r37","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer.","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"27","key":"zoi190711r38","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi190711r39","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1016\/j.ejca.2010.06.124","article-title":"Paclitaxel\/carboplatin versus topotecan\/paclitaxel\/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer: a multicenter, randomized study.","volume":"46","author":"Bolis","year":"2010","journal-title":"Eur J Cancer"},{"issue":"9","key":"zoi190711r40","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup.","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi190711r41","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2007.14.9807","article-title":"Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.","volume":"26","author":"Lhomm\u00e9","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi190711r42","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","article-title":"Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens.","volume":"24","author":"du Bois","year":"2006","journal-title":"J Clin Oncol"},{"issue":"30","key":"zoi190711r43","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer.","volume":"32","author":"du Bois","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi190711r44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ygyno.2013.04.011","article-title":"A randomized phase II trial of maintenance therapy with sorafenib in front-line ovarian carcinoma.","volume":"130","author":"Herzog","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"25","key":"zoi190711r45","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1200\/JCO.2012.44.9116","article-title":"Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.","volume":"31","author":"Vergote","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi190711r46","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ygyno.2012.04.050","article-title":"Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.","volume":"126","author":"Meier","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"28","key":"zoi190711r47","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2009.21.9691","article-title":"Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel\/platinum-based chemotherapy: final results of the After-6 protocol 1.","volume":"27","author":"Pecorelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi190711r48","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.","volume":"98","author":"Pfisterer","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"zoi190711r49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ygyno.2009.04.012","article-title":"Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg\/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a SWOG and GOG phase 3 trial.","volume":"114","author":"Markman","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"zoi190711r50","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ygyno.2011.08.018","article-title":"Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.","volume":"123","author":"Gordon","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"zoi190711r51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"zoi190711r52","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1200\/JCO.2012.46.4057","article-title":"Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO\u2014the MIMOSA study.","volume":"31","author":"Sabbatini","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1B","key":"zoi190711r53","first-page":"681","article-title":"A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.","volume":"27","author":"Mouratidou","year":"2007","journal-title":"Anticancer Res"},{"issue":"5","key":"zoi190711r54","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/cam4.376","article-title":"Paclitaxel\/carboplatin with or without sorafenib in the first-line treatment of patients with stage III\/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.","volume":"4","author":"Hainsworth","year":"2015","journal-title":"Cancer Med"},{"issue":"13","key":"zoi190711r55","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1200\/JCO.2004.09.088","article-title":"Topotecan compared with no therapy after response to surgery and carboplatin\/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.","volume":"22","author":"De Placido","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi190711r56","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/j.1525-1438.2007.00862.x","article-title":"Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer.","volume":"17","author":"Nicoletto","year":"2007","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"zoi190711r57","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","article-title":"National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin Chem"},{"issue":"4","key":"zoi190711r58","first-page":"370","article-title":"Correlation of progression-free and post-progression survival with overall survival in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer.","volume":"36","author":"Shimokawa","year":"2015","journal-title":"Eur J Gynaecol Oncol"},{"issue":"5","key":"zoi190711r59","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12032-017-0939-9","article-title":"Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.","volume":"34","author":"Colloca","year":"2017","journal-title":"Med Oncol"},{"key":"zoi190711r60","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer [published online September 28, 2019].","author":"Gonz\u00e1lez-Mart\u00edn","journal-title":"N Engl J Med"},{"key":"zoi190711r13","first-page":"163","volume-title":"The Evaluation of Surrogate Endpoints","author":"Burzykowski"},{"key":"zoi190711r61","unstructured":"Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics. Published December 2018. Accessed September 30, 2019."},{"key":"zoi190711r62","unstructured":"European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf. Published September 22, 2017. Accessed September 30, 2019."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2758473\/paoletti_2020_oi_190711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T18:58:47Z","timestamp":1578682727000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2758473"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18939","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]}}}